HORIZON: Rocatinlimab Effective in Adults With Atopic Dermatitis
网页2 天之前 · The randomized, double-blind, placebo-controlled ROCKET HORIZON study (ClinicalTrials.gov Identifier: NCT05651711) evaluated the safety and efficacy of rocatinlimab, an anti-OX40 antibody, in adults with moderate to severe atopic dermatitis. Study participants (N=726) were randomly assigned to receive rocatinlimab or placebo administered as a ...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 …
网页4 天之前 · Rocatinlimab Met Co-Primary Endpoints of vIGA-AD TM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints; HORIZON is the First of Eight Phase 3 Trials in the ...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase
网页3 天之前 · Rocatinlimab Met Co-Primary Endpoints of vIGA-AD TM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints; HORIZON is the First of Eight Phase 3 Trials in the ROCKET Program; TOKYO, Sept. 25, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial ...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 …
网页4 天之前 · Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ...
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis …
网页4 天之前 · Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease. 32.8% of rocatinlimab-treated subjects achieved an EASI-75 response at week 24 vs. 13.7% ...
Amgen reports success for eczema and myasthenia gravis …
网页4 天之前 · In its eczema trial, Amgen reported that its drug, rocatinlimab, outperformed a placebo in reducing outbreaks of red, itchy lesions. After 24 weeks, 32.8% of patients on the drug saw at least a...
Rocatinlimab exhibits positive results in phase 3 study for atopic ...
网页3 天之前 · Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release. Rocatinlimab is an ...
New Treatment for Moderate to Severe Atopic Dermatitis Shows …
网页2022年12月9日 · The results support rocatinlimab as a safe and effective treatment for moderate to severe atopic dermatitis, with potentially long-lasting efficacy and disease modification. Adverse events reported were generally similar between rocatinlimab groups.
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis
网页In their multicentre, double-blind, placebo-controlled phase 2b study, Emma Guttman-Yassky and colleagues showed the efficacy and safety of subcutaneous rocatinlimab versus subcutaneous placebo for the treatment of moderate-to-severe atopic dermatitis. 1 Although the findings of this study are novel and encouraging, there are a few limitations ...
Collaborating to Address Moderate to Severe Atopic Dermatitis
网页2023年1月19日 · The latest findings from Phase 2b of the ongoing clinical study, recently published in The Lancet, support the continued evaluation of rocatinlimab for the treatment of moderate to severe atopic dermatitis in Phase 3 studies.